A macroporous bioreactor super activated by the recombinant human transforming growth factor-β 3

Frontiers in Physiology

Volumn 3 JUN, Issue , 2012, Pages

  Ripamonti, Ugo ^a   Teare, June ^a   Ferretti, Carlo ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Biomimetic matrices; Coral derived macroporous constructs; Osteogenic proteins; Transforming growth factor 3

Indexed keywords

EID: 84866398639     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00172     Document Type: Article

References (61)

1. Carragee, E. J., Ghanayem, A. J., Weiner, B. K., Rothman, D. J., and Bono, C. M. (2011a). A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors. Spine J. 11, 463-468.
2. Carragee, E. J., Hurwitz, E. L., and Weiner, B. K. (2011b). A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 11, 471-491.
3. Centre for Devices and Radiological Health. (2011). Public Health Notifications (Medical Devices) -FDA Public Health Notification: Life Threatening Complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion. Available at: http:// www.fda.gov/MedicalDevices/Safety/ AlertsandNotices/PublicHealthNotif ications/ucm062000.htm
4. Chung, F. H. (1974). Quantitative interpretation of X-ray diffraction patterns, 1. Matrix flushing method of quantitative multicomponent analysis. J. Appl. Crystallogr. 7, 513-519.
5. Department of Justice. (2009). Acting United States Attorney Michael K. Loucks, District of Massachusetts. Stryker Biotech and its Top Management Indicated for Illegal Promotion of Medical Devices Used in Invasive Surgeries. Available at: http://www.usdoj.gov/usao/ma
6. Discher, D. E., Janmey, P., and Wang, Y. L. (2005). Tissue cells feel and respond to the stiffnes of their substrate. Science 310, 1139-1143.
7. Duneas, N., Crooks, J., and Ripamonti, U. (1998). Transforming growth factor-β1: induction of bone mor-phogenetic protein genes expression during endochondral bone formation in the baboon, and syn-ergistic interaction with osteogenic protein-1 (BMP-7). Growth Factors 15, 259-277.
8. Fauber, J. (2011a). Study Finds Increased Cancer Risk with Bone Growth Product. Journal Sentinel 2011. Available at: http://www. jsonline.com/watchdog/watchdogre ports/study-finds-increased-cancer-risk-with-bone-growth-product-133 208028.html [accessed November. 30,2011].
9. Fauber, J. (2011b). Complication from Spinal Product Omitted from Articles: Co-Authors Received Royalties from Manufacturer. Milwaukee J Sentinel 2011. Available at: http:// www.jsonline.com/features/health/ I22553058.html
10. Friedlaender, G. E., Perry, C. R., Dean Cole, J., Cook, S. D., Cierny, G., Muschler, G. F., Zych, G. A., Calhoun, J.H., Laforte, A.J.,andYin, S. (2001). Osteogenic protein-1 (bone mor-phogenetic protein-7) in the treatment of tibial nonunions. J. Bone JointSurg. Am. 83-A, 151-158.
11. Garrison, K. R., Donell, S., Ryder, J., Shemilt, I., Mugford, M., Harvey, I., and Song, F. (2007). Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol. Assess. 11, 1-150, iii-iv.
12. Govender, S., Csimma, C., Genant, H. K., Valentin-Opran, A., Amit, Y., Arbel, R., Aro, H., Atar, D., Bishay, M., Borner, M. G., Chiron, P., Choong, P., Cinats, J., Courtenay, B., Feibel, R., Geulette, B., Gravel, C., Haas, N., Raschke, M., Hammacher, E., Van Der Velde, D., Hardy, P., Holt, M., Josten, C., Ketterl, R. L., Lindeque, B., Lob, G., Mathevon, H., McCoy, G., Marsh, D., Miller, R., Munting, E., Oevre, S., Nordsletten, L., Patel, A., Pohl, A., Rennie, W., Reynders, P., Rommens, P. M., Rondia, J., Rossouw, W. C., Daneel, P. J., Ruff, S., Ruter, A., Santavirta, S., Schildhauer, T. A., Gekle, C., Schnettler, R., Segal, D., Seiler, H., Snowdowne, R. B., Stapert, J., Taglang, G., Verdonk, R., Vogels, L., Weckbach, A., Wentzensen, A., and Wisniewski, T. (2002). Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients.J. BoneJointSurg. Am. 84-A, 2123-2134.
13. Khouri, R. K., Koudsi, B., and Reddi, H. (1991). Tissue transformation into bone in vivo. a potential practical application. JAMA 266, 1953-1955.
14. Kovacic, J. C., and Boehm, M. (2009). Resident vascular progenitor cells: an emerging role for non-terminally differentiated vessel-resident cells in vascular biology. Stem Cell Res 2, 2-15.
15. Lander, A. D. (2007). Morpheus unbound: reimagining the morphogen gradient. Cell 128,245-256.
16. Miyazono, K., Kusanagi, K., and Inoue, H. (2001). Divergence and convergence of tgf-beta/bmp signaling. J. Cell. Physiol. 187, 265-276.
17. Mussano, F., Ciccone, G., Ceccarelli, M., Baldi, I., and Bassi, F. (2007). Bone morphogenetic proteins and bone defects: a systematic review. Spine 32, 824-830.
18. Nilen, R. W., and Richter, P. W. (2008). The thermal stability of hydroxyap-atite in biphasic calcium phosphate ceramics. J. Mater. Sci. Mater. Med. 19,1693-1702.
19. O'Keefe, R. J., and Mao, J. (2011). Bone tissue engineering and regeneration: from discovery to the clinic - an overview. Tissue Eng Part B Rev. 17, 389-392.
20. Özkaynak, E., Rueger, D. C., Drier, E. A., Corbett, C., Ridge, R. J., Sampath, T. K., and Oppermann, H. (1990). OP-1 cdna encodes an osteogenic protein in the TGF-β family. EMBOJ. 9, 2085-2093.
21. Parfitt, A. M. (1983). "Stereologic basis of bone histomorphometry: theory of quantitative microscopy and reconstruction of third dimension," in Bone Histomorphometry: Techniques and Interpretation, ed. H. R. Recker (Boca Raton: CRC Press), 53-87.
22. Public Services Department. (1990). National Code for Animal Use in Research, Education, Diagnosis, and Testing of Drugs, and Related Substances in South Africa. Pretoria: Public Services Department.
23. Reddi, A. H. (1984). "Extracellular matrix and development," in Extracellular Matrix Biochemistry, eds K. A. Piez and A. H. Reddi (New York: Elsevier), 375.
24. Reddi, A. H. (1994). Bone and cartilage differentiation. Curr. Opin. Genet. Dev. 4, 737-744.
25. Reddi, A. H. (1997). Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev. 8, 11-20.
26. Reddi, A. H. (1998). Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat. Biotechnol. 16,247-252.
27. Reddi, A. H. (2000). Morphogenesis and tissue engineering of bone and cartilage: inductive signals, stem cells, and biomimetic biomaterials. Tissue Eng. 6,351-359.
28. Ripamonti, U. (1991a). The morphogenesis of bone in replicas of porous hydroxyapatite obtained from conversion of calcium carbonate exoskeletons of coral. J. Bone Joint Surg. Am. 73, 692-703.
29. Ripamonti, U. (1991b). Bone induction in nonhuman primates. an experimental study on the baboon. Clin. Orthop. Relat. Res. 269, 284-294.
30. Ripamonti, U. (2004). Soluble, insoluble and geometric signals sculpt the architecture of mineralized tissues. J. CellMol. Med. 8,169-180.
31. Ripamonti, U. (2005). Bone induction by recombinant human osteogenic protein-1 (hOP-1, BMP-7) in the primate Papio ursinus with expression of mRNA of gene products of the TGF-β superfamily. J. Cell Mol. Med. 9, 911-928.
32. Ripamonti, U. (2006a). Soluble osteogenic molecular signals and the induction of bone formation. Biomaterials 27, 807-822.
33. Ripamonti, U. (2006b). "The Marshall Urist Awarded Lecture - Bone: formation by autoinduction," in Proceedings of the 6th International Conference on BMP's, 11-16 October 2006, eds S. Vukicevic and A. H. Reddi (Dubrovnick), 1. Available at: http://www.depol.org
34. Ripamonti, U., Crooks, J., and Kirkbride, A. N. (1999). Sintered porous hydroxyapatites with intrinsic osteoinductive activity: geometric induction of bone formation. S. Afr. J. Sci. 95, 335-343.
35. Ripamonti, U., Crooks, J., Matsaba, T., and Tasker, J. (2000a). Induction of endochondral bone formation by recombinant human transforming growth factor-β2 in the baboon (Papio ursinus). Growth Factors 17, 269-285.
36. Ripamonti, U., van den Heever, B., Crooks, J., Tucker, M. M., Sampath, T. K., Rueger, D. C., and Reddi, A. H. (2000b). Long-term evaluation of bone formation by osteogenic protein 1 in the baboon and relative efficacy of bone-derived bone morphogenetic proteins delivered by irradiated xenogeneic col-lagenous matrices. J. Bone Miner. Res. 15, 1798-1809.
37. Ripamonti, U., Duneas, N., van den Heever, B., Bosch, C., and Crooks, J. (1997). Recombinant transforming growth factor-β1 induces endochondral bone in the baboon and synergizes with recombinant osteogenic protein-1 (bone morphogenetic protein-7) to initiate rapid bone formation. J. BoneMiner. Res. 12, 1584-1595.
38. Ripamonti, U., and Ferretti, C. (2012). "Grand challenges for craniomandibulofacial recon-struction by human recombinant transforming growth fcator-β3," in Proceedings of the Keystone Symposia on Regenerative Tissue Engineering and Transplantation, 1-6 April, eds R. S. Tuan, F.Guilak, and A. Atala (Breckenridge, CO: Keystone Symposia Molecular and Cellular Biology). Available at: http://www.keystonesymposia.org
39. Ripamonti, U., Ferretti, C., and Heli-otis, M. (2006). Soluble and insoluble signals and the induction of bone formation: molecular therapeutics recapitulating development. J. Anat. 209,447-468.
40. Ripamonti, U., Ferretti, C., Teare, J., and Blann, L. (2009a). Transforming growth factor-β isoforms and the induction of bone formation: implications for reconstructive craniofa-cial surgery. J. Craniofac. Surg. 20, 1544-1555.
41. Ripamonti, U., Crooks, J., Khoali, L., and Roden, L. (2009b). The induction of bone formation by coral-derived calcium carbonate/hydroxyapatite constructs. Biomaterials 30, 1428-1439.
42. Ripamonti, U., Heliotis, M., and Ferretti, C. (2007a). Bone morphogenetic proteins and the induction of bone formation: from laboratory to patients. Oral Maxillofac. Surg. Clin. North Am. 19, 575-589, vii.
43. Ripamonti, U., Richter, P. W., and Thomas, M. E. (2007b). Self-inducing shape memory geometric cues embedded within smart hydroxyapatite-based biomimetic matrices. Plast. Reconstr. Surg. 120, 1796-1807.
44. Ripamonti, U., Klar, R. M., Renton, L. E, and Ferretti, C. (2010). Synergistic induction of bone formation by hOP-1, hTGF-β3 and inhibition by zoledronate in macroporous coral-derived hydroxyapatites. Biomaterials 31, 6400-6410.
45. Ripamonti, U., Ma, S. S., and Reddi, A. H. (1992). Induction of bone in composites of osteogenin and porous hydroxyapatite in baboons. Plast. Reconstr. Surg. 89, 731-739.
46. Ripamonti, U., Ramoshebi, L. N., Matsaba, T., Tasker, J., Crooks, J., and Teare, J. (2001). Bone induction by BMPs/OPs and related family members in primates. J. Bone Joint Surg. Am. 83-A(Suppl. 1), S116-S127.
47. Ripamonti, U., Ramoshebi, L. N., Teare, J., Renton, L., and Ferretti, C. (2008). The induction of endochon-dral bone formation by transforming growth factor-β3: experimental studies in the non-human primate Papio ursinus. J. Cell Mol. Med. 12, 1029-1048.
48. Ripamonti, U., and Roden, L. C. (2010). Induction of bone formation by transforming growth factor-β2 in the non-human primate Papio ursinus and its modulation by skeletal muscle responding stem cells. Cell Prolif. 43, 207-218.
49. Ripamonti, U., van den Heever, B., Sampath, T. K., Tucker, M. M., Rueger, D. C., and Reddi, A. H. (1996). Complete regeneration of bone in the baboon by recombinant human osteogenic protein-1 (hOP-1, bone morphogenetic protein-7). Growth Factors 13,273-289.
50. Ripamonti, U., van den Heever, B., and Van Wyk, J. (1993). Expression of the osteogenic phenotype in porous hydroxyapatite implanted extraskeletally in baboons. Matrix 13,491-502.
51. Sampath, T.K., and Reddi, A. H. (1981). Dissociative extraction and reconsti-tution of extracellular matrix components involved in local bone differentiation. Proc. Natl. Acad. Sci. U.S.A. 78, 7599-7603.
52. Sampath, T.K., and Reddi, A. H. (1983). Homology of bone-inductive proteins from human, monkey, bovine, and rat extracellular matrix. Proc. Natl. Acad. Sci. U.S.A. 80, 6591-6595.
53. Schnitzler, C. M., Ripamonti, U., and Mesquita, J. M. (1993). Histomorphometry of iliac crest trabecular bone in adult male baboons in captivity. Calcif. Tissue Int. 52, 447-454.
54. Shors, E. C. (1999). Coralline bone graft substitutes. Orthop. Clin. North Am. 30,599-613.
55. Slack, J. M. W. (1987). Morphogenetic gradients - past and present. Trends Biochem. Sci. 12, 200-204.
56. Trueta, J. (1963). The role of vessels in osteogenesis. J. Bone Joint Surg. Br. 45B, 402-418.
57. US Food and Drug Administration. (2008). US Food and Drug Administration Public Health Notification. Life-Threatening Complications Associatedwith Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion. US Food and Drug Administration: 2008. Available at: http://www.fda.gov/cdrh/safety/070 108-rhbmp.html [accessed June 1, 2011].
58. Viola, J., Lal, B., and Grad, O. (2003). National Science Foundation ABT Report on: The Emergence of Tissue Engineering as a Research Field. Available at: http://www.abta ssoc.org/reports/Emergence_Tissue_ Engineering_Research.pdf
59. Williams, B. J., Smith, J. S., Fu, K.-M., Hamilton, D. K., Perra, J., Polly, D., Ames, C., Berven, S., Glassman, S., Knapp, R., and Shaffrey, C. (2010). Complications associated with BMP use in 11,933 cases of spinal fusion. Spine J. 10, S98-S99.
60. Williams, D. E (2006). "Tissue engineering: the multidisciplinary epitome of hope and despair," in Studies in Multidisciplinarity, eds R. Paton and L. McNa-mara (Amsterdam: Elsevier BV), 483-524.
61. Wozney, J. M., Rosen, V., Celeste, A. J., Mitsock, L. M., Whitters, M. J., Kriz, R. W., Hewick, R. M., and Wang, E. A. (1988). Novel regulators of bone formation: molecular clones and activities. Science 242, 1528-1534.